Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease

BMS's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease ...

Bristol Myers Gets FDA Fast-Track Designation for BMS-986446 in Alzheimer's

Bristol Myers Squibb has won Food and Drug Administration fast-track designation for its BMS-986446 drug candidate in Alzheimer's disease. Bristol Myers on Wednesday said BMS-986446 is a potential ...